From 18 F-choline to prostate-specific membrane antigen PET: lessons from early multiparametric kinetic modelling in prostate cancer.

Comparison of automated robotic arm-assisted PET/computed tomography-guided metabolic bone marrow biopsy with conventional bone marrow trephine biopsy for evaluating bone marrow infiltration in newly diagnosed lymphoma.

Assessment of fundal accommodation in solid meal gastric emptying scintigraphy: a retrospective analysis.

Role of fluorodeoxyglucose positron emission tomography scan in assessing the extent of myocardial viability in patients with left ventricular dysfunction and its impact on patient outcome.

Additional detection of Bethesda greater than or equal to III cytology in cold thyroid nodules beyond American College of Radiology Thyroid Imaging Reporting and Data System risk stratification.

Efficacy of intra-arterial [ 177 Lu]Lu-DOTATATE vs. continuation intravenous [ 177 Lu]Lu-DOTATATE peptide receptor radionuclide therapy in nonresponding locally advanced inoperable or liver-dominant metastatic gastroenteropancreatic neuroendocrine tumors.

From 18 F-choline to prostate-specific membrane antigen PET: lessons from early multiparametric kinetic modelling in prostate cancer.

Comparison of automated robotic arm-assisted PET/computed tomography-guided metabolic bone marrow biopsy with conventional bone marrow trephine biopsy for evaluating bone marrow infiltration in newly diagnosed lymphoma.

Assessment of fundal accommodation in solid meal gastric emptying scintigraphy: a retrospective analysis.

Role of fluorodeoxyglucose positron emission tomography scan in assessing the extent of myocardial viability in patients with left ventricular dysfunction and its impact on patient outcome.

Additional detection of Bethesda greater than or equal to III cytology in cold thyroid nodules beyond American College of Radiology Thyroid Imaging Reporting and Data System risk stratification.

Efficacy of intra-arterial [ 177 Lu]Lu-DOTATATE vs. continuation intravenous [ 177 Lu]Lu-DOTATATE peptide receptor radionuclide therapy in nonresponding locally advanced inoperable or liver-dominant metastatic gastroenteropancreatic neuroendocrine tumors.